Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
- PMID: 8674031
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
Abstract
Flavopiridol (L86-8275), a N-methylpiperidinyl, chlorophenyl flavone, can inhibit cell cycle progression in either G1 or G2 and is a potent cyclin-dependent kinase (CDK) 1 inhibitor. In this study, we used MCF-7 breast carcinoma cells that are wild type for p53 and pRb positive and contain CDK4-cyclin D1 and MDA-MB-468 breast carcinoma cells that are mutant p53, pRb negative, and lack CDK4-cyclin D1 to investigate the G1 arrest produced by Flavopiridol. Recombinant CDK4-cyclin D1 was inhibited potently by Flavopiridol (Kiapp, 65 nM), competitive with respect to ATP. Surprisingly, CDK4 immunoprecipitates derived from Flavopiridol-treated MCF-7 cells (3 h, 300 nM Flavonolpiridol) had an approximately 3-fold increased kinase activity compared with untreated cells. Cyclin D and CDK4 levels were not different at 3 hr, but cyclin D levels and CDK4 kinase activity decreased thereafter. The phosphorylation state of pRb was shifted from hypercoincident to hypocoincident with the development of G1 arrest. Asynchronous MDA-MB-468 cells were inhibited in cell cycle progression at both G1 and G2 by Flavopiridol. Flavopiridol inhibited the in vitro kinase activity of CDK2 using an immune complex kinase assay (IC50, 100 nM at 400 microM ATP). Immunoprecipitated CDK2 kinase activity from either MCF-7 or MDA-MB-468 cells exposed to Flavopiridol (300 nM) for increasing time showed an initial increased activity (approximately 1.5-fold at 3 h) compared with untreated cells, followed by a loss of kinase activity to immeasurable levels by 24 h. This increased immunoprecipitated kinase activity was dependent on the Flavopiridol concentration added to intact cells and was associated with a reduction of CDK2 tyrosine phosphorylation. Cyclin E and A levels were not altered to the same extent as cyclin D, and neither CDK4 nor CDK2 levels were changed in response to Flavopiridol. Inhibition of the CDK4 and/or CDK2 kinase activity by Flavopiridol can therefore account for the G1 arrest observed after exposure to Flavopiridol.
Similar articles
-
Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.Clin Cancer Res. 2000 Mar;6(3):924-32. Clin Cancer Res. 2000. PMID: 10741717
-
Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.Cancer Res. 1999 Sep 15;59(18):4634-41. Cancer Res. 1999. PMID: 10493518
-
Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.Oncogene. 1998 Nov 5;17(18):2393-402. doi: 10.1038/sj.onc.1202322. Oncogene. 1998. PMID: 9811471
-
The cell cycle kinases.Semin Cancer Biol. 1994 Aug;5(4):305-13. Semin Cancer Biol. 1994. PMID: 7803767 Review.
-
[Cyclin D, CDK4 and p16 expression in colorectal cancer].Nihon Rinsho. 1996 Apr;54(4):1054-9. Nihon Rinsho. 1996. PMID: 8920673 Review. Japanese.
Cited by
-
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.Blood. 2012 Aug 9;120(6):1262-73. doi: 10.1182/blood-2011-12-400184. Epub 2012 Jun 27. Blood. 2012. PMID: 22740450 Free PMC article.
-
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Curr Pharm Des. 2012;18(20):2883-90. doi: 10.2174/138161212800672750. Curr Pharm Des. 2012. PMID: 22571657 Free PMC article. Review.
-
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.J Clin Oncol. 2010 Jan 20;28(3):418-23. doi: 10.1200/JCO.2009.24.1570. Epub 2009 Dec 14. J Clin Oncol. 2010. PMID: 20008633 Free PMC article. Clinical Trial.
-
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.Invest New Drugs. 2011 Oct;29(5):1004-12. doi: 10.1007/s10637-010-9447-x. Epub 2010 May 12. Invest New Drugs. 2011. PMID: 20461440 Free PMC article. Clinical Trial.
-
Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.J Clin Invest. 2010 Jun;120(6):2109-18. doi: 10.1172/JCI39964. Epub 2010 May 17. J Clin Invest. 2010. PMID: 20484815 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous